Primary Care Rx Market Offers Second-Rate Return On Investment – Bristol
Executive Summary
Pharmaceutical companies marketing primary care products are unlikely to see a significant return on their investment, Bristol-Myers Squibb CFO Andrew Bonfield declared June 10